Differential body composition effects of protease inhibitors recommended for initial treatment of HIV infection: a randomized clinical trial (Q41666586)

From Wikidata

Jump to navigation Jump to search

scientific article published on 10 November 2014

Language	Label	Description	Also known as
English	Differential body composition effects of protease inhibitors recommended for initial treatment of HIV infection: a randomized clinical trial	scientific article published on 10 November 2014

Statements

scholarly article

1 reference

Europe PubMed Central

6 October 2017

Differential body composition effects of protease inhibitors recommended for initial treatment of HIV infection: a randomized clinical trial (English)

1 reference

Europe PubMed Central

6 October 2017

Eugènia Negredo

5

object named as

Eugenia Negredo

1 reference

Europe PubMed Central

6 October 2017

Daniel Podzamczer

9

object named as

Daniel Podzamczer

1 reference

Europe PubMed Central

6 October 2017

Félix Gutiérrez

object named as

Felix Gutierrez

6

0 references

Joaquim Peraire

object named as

Joaquim Peraire

15

0 references

object named as

Esteban Ribera

10

0 references

Josep Maria Gatell

19

object named as

Jose M Gatell

1 reference

Europe PubMed Central

6 October 2017

Javier Murillas

11

object named as

Javier Murillas

1 reference

Europe PubMed Central

6 October 2017

16

object named as

Judit Pich

1 reference

Europe PubMed Central

6 October 2017

author name string

Esteban Martinez

1

1 reference

Europe PubMed Central

6 October 2017

Ana Gonzalez-Cordon

2

1 reference

Europe PubMed Central

6 October 2017

Elena Ferrer

3

1 reference

Europe PubMed Central

6 October 2017

Pere Domingo

4

1 reference

Europe PubMed Central

6 October 2017

Joaquin Portilla

7

1 reference

Europe PubMed Central

6 October 2017

Adrià Curran

8

1 reference

Europe PubMed Central

6 October 2017

Jose I Bernardino

12

1 reference

Europe PubMed Central

6 October 2017

Ignacio Santos

13

1 reference

Europe PubMed Central

6 October 2017

Jose A Carton

14

1 reference

Europe PubMed Central

6 October 2017

Ramon Deulofeu

17

1 reference

Europe PubMed Central

6 October 2017

Ignacio Perez

18

1 reference

Europe PubMed Central

6 October 2017

ATADAR Study Group

20

1 reference

Europe PubMed Central

6 October 2017

language of work or name

0 references

publication date

10 November 2014

1 reference

Europe PubMed Central

6 October 2017

Clinical Infectious Diseases

1 reference

Europe PubMed Central

6 October 2017

60

1 reference

Europe PubMed Central

6 October 2017

811-820

1 reference

Europe PubMed Central

6 October 2017

5

1 reference

Europe PubMed Central

6 October 2017

Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU898

21 January 2018

Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU898

21 January 2018

Postprandial lipid effects of low-dose ritonavir vs. raltegravir in HIV-uninfected adults

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU898

21 January 2018

Boosting dose ritonavir does not alter peripheral insulin sensitivity in healthy HIV-seronegative volunteers

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU898

21 January 2018

Effects of ritonavir-boosted darunavir vs. ritonavir-boosted atazanavir on lipid and glucose parameters in HIV-negative, healthy volunteers

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU898

21 January 2018

Pharmacokinetics of once-daily darunavir-ritonavir and atazanavir-ritonavir over 72 hours following drug cessation

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU898

21 January 2018

Peripheral and central fat changes in subjects randomized to abacavir-lamivudine or tenofovir-emtricitabine with atazanavir-ritonavir or efavirenz: ACTG Study A5224s

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU898

21 January 2018

Comparison of body composition changes between atazanavir/ritonavir and lopinavir/ritonavir each in combination with tenofovir/emtricitabine in antiretroviral-naïve patients with HIV-1 infection

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU898

21 January 2018

Clinical pharmacology, efficacy and safety of atazanavir: a review.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU898

21 January 2018

Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeks

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU898

21 January 2018

Early lipid changes with atazanavir/ritonavir or darunavir/ritonavir

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU898

21 January 2018

A new equation to estimate glomerular filtration rate

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU898

21 January 2018

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU898

21 January 2018

A simple, rapid, highly sensitive and reproducible quantification method for plasma malondialdehyde by high-performance liquid chromatography

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU898

21 January 2018

CONSORT 2010 Explanation and Elaboration: Updated guidelines for reporting parallel group randomised trials.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU898

21 January 2018

Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU898

21 January 2018

Drug resistance in HIV-1.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU898

21 January 2018

Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU898

21 January 2018

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, d

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU898

21 January 2018

Clinical significance of hyperbilirubinemia among HIV-1-infected patients treated with atazanavir/ritonavir through 96 weeks in the CASTLE study

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU898

21 January 2018

Are hypertriglyceridemia and low HDL causal factors in the development of insulin resistance?

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU898

21 January 2018

Overweight and human immunodeficiency virus (HIV) progression in women: associations HIV disease progression and changes in body mass index in women in the HIV epidemiology research study cohort

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU898

21 January 2018

Human immunodeficiency virus treatment-induced adipose tissue pathology and lipoatrophy: prevalence and metabolic consequences

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU898

21 January 2018

Preferential fat deposition in subcutaneous versus visceral depots is associated with insulin sensitivity

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU898

21 January 2018

HIV-associated lipodystrophy: impact of antiretroviral therapy.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU898

21 January 2018

Abdominal subcutaneous adipose tissue: a protective fat depot?

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU898

21 January 2018

Impact of switching from lopinavir/ritonavir to atazanavir/ritonavir on body fat redistribution in virologically suppressed HIV-infected adults

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU898

21 January 2018

Effects of ritonavir-boosted darunavir, atazanavir and lopinavir on adipose functions and insulin sensitivity in murine and human adipocytes.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU898

21 January 2018

Identifiers

10.1093/CID/CIU898

1 reference

Europe PubMed Central

6 October 2017

1 reference

Europe PubMed Central

6 October 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41666586&oldid=1925679275"